Abstract
Cardiovascular disease (CVD) is prevalent in patients with chronic kidney disease (CKD). In hemodialysis (HD) patients, some protein-bound uremic toxins are considered to be associated with CVD. However, it is not yet known which uremic toxins are important in terms of endothelial toxicity. Serum samples were obtained from 45 HD patients before and after HD. Total and free serum concentrations of indoxyl sulfate, indoxyl glucuronide, indoleacetic acid, p-cresyl sulfate, p-cresyl glucuronide, phenyl sulfate, phenyl glucuronide, phenylacetic acid, phenylacetyl glutamine, hippuric acid, 4-ethylphenyl sulfate, and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) were simultaneously measured by liquid chromatography/electrospray ionization–mass spectrometry/mass spectrometry (LC/ESI-MS/MS). The effects of these solutes at their pre-HD mean and maximum serum concentrations on reactive oxygen species (ROS) production in human umbilical vein endothelial cells (HUVEC) were measured with a ROS probe. Serum levels of 11 of the solutes (all except 4-ethylphenyl sulfate) were significantly increased in HD patients compared to healthy subjects. All 12 solutes showed changes in their protein-binding ratios. In particular, indoxyl sulfate, p-cresyl sulfate, CMPF, and 4-ethylphenyl sulfate showed high protein-binding ratios (>95 %) and low reduction rates by HD (<35 %). Indoxyl sulfate at its mean and maximum pre-HD serum concentrations—even with 4 % albumin—stimulated ROS production in HUVEC most intensely, followed by CMPF. In conclusion, the serum levels of 11 protein-bound uremic toxins were increased in HD patients. Indoxyl sulfate, p-cresyl sulfate, and CMPF could not be removed efficiently by HD due to their high protein-binding ratios. Indoxyl sulfate most intensely induced endothelial ROS production, followed by CMPF.
Similar content being viewed by others
References
Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W, European Uremic Toxin Work Group (EUTox) (2003) Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63:1934–1943
Yavuz A, Tetta C, Ersoy FF, D'intini V, Ratanarat R, De Cal M, Bonello M, Bordoni V, Salvatori G, Andrikos E, Yakupoglu G, Levin NW, Ronco C (2005) Uremic toxins: a new focus on an old subject. Semin Dial 18:203–211
Niwa T (2011) Update of uremic toxin research by mass spectrometry. Mass Spectrom Rev 30:510–521
Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P (2009) Protein-bound toxins—update 2009. Semin Dial 22:334–339
Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T (2010) Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J Chromatogr B 878:1662–1668
Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T (2010) Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B 878:2997–3002
Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P (2011) Vascular incompetence in dialysis patients—protein-bound uremic toxins and endothelial dysfunction. Semin Dial 24:327–337
Annuk M, Zilmer M, Lind L, Linde T, Fellström B (2001) Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 12:2747–2752
Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P (2007) The uremic solute indoxyl sulphate induces oxidative stress in endothelial cells. J Thromb Haemost 5:1302–1308
Tumur Z, Niwa T (2009) Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells. Am J Nephrol 29:551–557
Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T (2010) Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kB activation. Am J Nephrol 31:435–441
Nakai D, Kumamoto K, Sakikawa C, Kosaka T, Tokui T (2004) Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci 93:847–854
Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, Meyer TW (2011) Colonic contribution to uremic solutes. J Am Soc Nephrol 22:1769–1776
Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G (2009) Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 106:3698–3703
Niwa T, Ise M (1994) Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 124:96–104
Niwa T, Ise M, Miyazaki T (1994) Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 14:207–212
Miyazaki T, Ise M, Seo H, Niwa T (1997) Indoxyl sulfate increases the gene expressions of TGF-β1, TIMP-1 and pro-α1(I) collagen in uremic rat kidneys. Kidney Int 52(S62):S15–S22
Enomoto A, Takeda M, Tojo A, Sekine T, Cha SH, Khamdang S, Takayama F, Aoyama I, Nakamura S, Endou H, Niwa T (2002) Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 13:1711–1720
Adijiang A, Goto S, Uramoto S, Nishijima F, Niwa T (2008) Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 23:1892–1901
Niwa T (2010) Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr 20(Suppl 1):S2–S6
Schepers E, Glorieux G, Vanholder R (2010) The gut: the forgotten organ in uremia? Blood Purif 29:130–136
Meijers BK, De Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P (2009) p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 4:1932–1938
Meijers B, Toussaint ND, Meyer T, Bammens B, Verbeke K, Vanrenterghem Y, Kerr PG, Evenepoel P (2011) Reduction in protein-bound solutes unacceptable as marker of dialysis efficacy during alternate-night nocturnal hemodialysis. Am J Nephrol 34:226–232
Jankowski J, van der Giet M, Jankowski V, Schmidt S, Hemeier M, Mahn B, Giebing G, Tolle M, Luftmann H, Schluter H, Zidek W, Tepel M (2003) Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 112:256–264
Meyer TW, Peattie JW, Miller JD, Dinh DC, Recht NS, Walther JL, Hostetter TH (2007) Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J Am Soc Nephrol 18:868–874
Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S (1997) The protein metabolite hypothesis, a model for the progression of renal failure: an oral sorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 52(Suppl 62):S23–S28
Conflict of interest
Y.I., A.E., and K.K. are employed by Kureha Corporation. The other authors declare no competing interests.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published in the special paper collection Biomedical Mass Spectrometry with guest editors Toyofumi Nakanishi and Mitsutoshi Setou.
Rights and permissions
About this article
Cite this article
Itoh, Y., Ezawa, A., Kikuchi, K. et al. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 403, 1841–1850 (2012). https://doi.org/10.1007/s00216-012-5929-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-012-5929-3